Company profile: Reviva Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage pharmaceutical therapies, including Brilaroxazine (RP5063), a serotonin and dopamine receptor modulator in development for neuropsychiatric conditions such as schizophrenia, bipolar disorder, major depressive disorder, Alzheimer's disease, Parkinson's disease psychosis, and ADHD, and RP1208, a triple reuptake inhibitor for depression and obesity.
Products and services
- Innovative Therapy Development: Architects receptor modulators and triple reuptake inhibitors for neuropsychiatric, depression, obesity, clinical-stage
- Brilaroxazine (RP5063): Engineers a serotonin/dopamine receptor modulator for schizophrenia, bipolar disorder, major depressive disorder, clinical-stage
- RP1208: Develops a triple reuptake inhibitor being developed for treating depression and obesity, investigational
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Reviva Pharma
Vanda Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on central nervous system disorders, developing and commercializing innovative products through clinical and commercial stage programs, including HETLIOZAccess: an expanded access program for Non-24-Hour Sleep-Wake Disorder (Non-24).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vanda Pharmaceuticals company profile →
Asceneuron
HQ: Switzerland
Website
- Description: Provider of small molecule drug discovery and therapeutics for neurodegenerative diseases, focusing on orphan tauopathies and Alzheimer’s disease. Portfolio includes ASN51, a clinical-stage O-GlcNAcase inhibitor targeting tau aggregation for Alzheimer’s, progressing into Phase II, and ASN90, an O-GlcNAcase inhibitor for PSP, licensed to Ferrer with completed Phase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Asceneuron company profile →
Cerebral Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapies and technology for direct-to-brain drug delivery, including CT-010, a proprietary valproic acid formulation delivered via an implanted, refillable catheter and pump for refractory epilepsy; the ICVRx platform enabling intracerebroventricular delivery of drugs, biologics, and oligonucleotide therapies; and clinical trials evaluating therapies for neurological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerebral Therapeutics company profile →
Sio Gene Therapies
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sio Gene Therapies company profile →
Neurelis
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies addressing unmet medical needs, including VALTOCO, a prescription nasal spray for short-term treatment of seizure clusters in patients aged 6 and older; and pipeline programs NRL-1004 for acute agitation using proprietary Intravail delivery technology, and NRL-1049 for cerebral cavernous malformations, potentially the first FDA-approved treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurelis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Reviva Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Reviva Pharma
2.2 - Growth funds investing in similar companies to Reviva Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Reviva Pharma
4.2 - Public trading comparable groups for Reviva Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →